Diagonal Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $253M
Overview
Pioneer in agonist antibody therapeutics that activate specific receptor complexes for disease treatment.
CardiovascularImmunology
Technology Platform
A proprietary platform for discovering and optimizing agonist antibodies that selectively activate target receptor complexes to restore physiological signaling.
Funding History
2Total raised:$253M
PIPE$125M
PIPE$128M
Opportunities
Potential to create first-in-class therapies for diseases with pathway deficiencies that are undruggable by traditional small molecules or antagonist antibodies.
Risk Factors
High biological risk of on-target toxicity or unintended signaling consequences from agonist antibody activity.
Competitive Landscape
Operates in a specialized niche with limited direct competition, but faces scientific skepticism around the feasibility and safety of systemic receptor agonism with antibodies.